Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 2:2014:421385.
doi: 10.1155/2014/421385. eCollection 2014.

Apathy in Alzheimer's disease: any effective treatment?

Raffaele Rea  1 , Anna Carotenuto  1 , Angiola M Fasanaro  2 , Enea Traini  3 , Francesco Amenta  3
Affiliations
Review

Apathy in Alzheimer's disease: any effective treatment?

Raffaele Rea et al. ScientificWorldJournal. .

Abstract

Objective: This review has evaluated the effectiveness of pharmacological treatment of apathy in patients with Alzheimer's disease (AD).

Methods: A systematic literature search was conducted on published clinical trials assessing the effects of pharmacological treatment on apathy in AD over the last 10 years.

Results: Fourteen studies considered of good quality were included in the analysis (4 randomized controlled trials, 9 open-label studies, and 1 retrospective analysis). Cholinesterase inhibitors were investigated in 9 studies, monoaminergic compounds such as methylphenidate and modafinil in two trials and one trial, respectively, and Ginkgo biloba (EGb 761 extract) and citalopram in one study each. Cholinesterase inhibitors did not show statistical significant effect in 1 RCT study but were associated to improvement in 3 open-label studies. Methylphenidate elicited a small but significant activity accompanied by relevant side effects such as high blood pressure, cough, and osteoarticular pain. EGb 761 was well tolerated and countered apathy. Other treatments induced modest improvements or were ineffective.

Conclusions: Apathy treatment remains a challenge and there is no evident advantage of any specific pharmacotherapy tested so far. The development of controlled studies according to updated guidelines for the diagnosis of apathy in patients with AD is desirable.

PubMed Disclaimer

References

    1. Stanton BR, Leigh PN, Howard RJ, Barker GJ, Brown RG. Behavioural and emotional symptoms of apathy are associated with distinct patterns of brain atrophy in neurodegenerative disorders. Journal of Neurology. 2013;260(10):2481–2490. - PubMed
    1. Marin RS. Differential diagnosis and classification of apathy. American Journal of Psychiatry. 1990;147(1):22–30. - PubMed
    1. Marin RS. Apathy: a neuropsychiatric syndrome. Journal of Neuropsychiatry and Clinical Neurosciences. 1991;3(3):243–254. - PubMed
    1. Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. Journal of Neuropsychiatry and Clinical Neurosciences. 1997;9(3):315–330. - PubMed
    1. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex. 2006;16(7):916–928. - PubMed

MeSH terms

Substances